MedPath

Role of regulatory T cells in the pathogenesis of atopic dermatitis and psoriasis vulgaris.

Withdrawn
Conditions
atopic dermatitis
eczema
psoriasis
10014982
Registration Number
NL-OMON33107
Lead Sponsor
niversitair Medisch Centrum Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
84
Inclusion Criteria

Atopic dermatitis patients:
- Adult (18-70 years) male or female patients diagnosed with atopic dermatitis
- Biopsy location (4x4 cm) should not be treated with topical steroids, dithranol or vitamin D3 preparations for at least 1 week;Psoriasis vulgaris patients:
- Adult (18-70 years) male or female patients diagnosed with psoriasis vulgaris
- Biopsy location (4x4 cm) should not be treated with topical steroids, dithranol or vitamin D3 preparations for at least 1 week;Healthy controls:
- Adult (18-70 years) male or female volunteers without a history of skin diseases
- Biopsy location (4x4 cm) should not be treated with topical steroids, dithranol or vitamin D3 preparations for at least 1 week
- No history of asthma and/or hay fever and/or house dust mite allergy;Patients undergoing plastic surgery:
- Adult (18-70 years of age) male or female patients without a history of skin diseases
- No history of asthma and/or hay fever and/or house dust mite allergy

Exclusion Criteria

- Use of systemic immunosuppressive drugs (i.e., cyclosporin, prednisolone, methotrexate, neotigasone, fumaric acid) in the 6 weeks prior to inclusion
- Exposure of biopsy location to (extraordinary) UV sunlight (i.e. UV-therapy, sunny holiday) in the weeks prior to inclusion
- (Secondary) skin infection

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Suppressive capacity of Tregs measured as suppression of proliferation by<br /><br>effector T cells (Teffs)<br /><br>(Tregs and Teffs will be co-cultured in the presence of antigen presenting<br /><br>cells. Teffs will be labeled with CFSE. Dilution of CFSE is a measure for<br /><br>proliferation) </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>not applicable</p><br>
© Copyright 2025. All Rights Reserved by MedPath